<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179607</url>
  </required_header>
  <id_info>
    <org_study_id>M0002-BEL-C201</org_study_id>
    <nct_id>NCT01179607</nct_id>
  </id_info>
  <brief_title>Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Phase II, Dose-titration Trial to Explore the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of M0002 in Cirrhotic Subjects With Ascites and Hypo- or Normonatraemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Movetis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Movetis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      M0002, an orally active, selective non-peptidergic antagonist of the vasopressin V2 receptor&#xD;
      inhibits vasopressin-induced water reabsorption from the kidney. Therefore the aquaretic&#xD;
      effect of M0002 has a potential clinical benefit in the treatment of ascites and&#xD;
      hyponatreamia in cirrhotic patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma sodium levels, weight, number of paracentesis</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cirrhotic Ascites</condition>
  <arm_group>
    <arm_group_label>M0002</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Started at 0.3 mg/day and increased every 3 days (to 1, 3 and 6 mg/day)&#xD;
for hyponatraemic subjects: dose was increased until the evening serum level was between 132 mmol/l and 145 mmol/l;&#xD;
for normonatraemic subjects the dose was increased until a 500 ml increase in the 24-h urine volume compared with Day-1 was reached.&#xD;
Once the required response or max dose was achieved, subjects entered a maintenance phase where they remained on the same dose of M0002 or placebo until 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M0002</intervention_name>
    <arm_group_label>M0002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with any form of cirrhosis with ascites and who had at least 1 paracentesis&#xD;
             of at least 4 liter in the last 6 months.&#xD;
&#xD;
          2. Dose of diuretics of spironolactone and furosemide was to be stable for at least one&#xD;
             week prior to the screening visit or subject was refractory to diuretics.&#xD;
&#xD;
          3. Subjects had to have been on a salt restricted diet (&lt; 5.2 grams sodium/day, 90 mmol)&#xD;
             during the screening period prior to the trial drug administration.&#xD;
&#xD;
          4. Other treatment for the management of cirrhosis and ascites should be stable for at&#xD;
             least 2 weeks prior to trial drug administration.&#xD;
&#xD;
          5. Child-Pugh B and C liver cirrhosis score lower than 12.&#xD;
&#xD;
          6. Subjects with hyponatraemia with sodium level between 120 and 132 mmol/l or&#xD;
             normonatraemia with sodium level between 133 and 145 mmol/l measured at screening&#xD;
             visit and day 1.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Women of child bearing potential (WOCBP)&#xD;
&#xD;
          2. Functional transjugular intrahepatic portasystemic stent shunt (TIPS), peritoneovenous&#xD;
             shunt&#xD;
&#xD;
          3. Liver transplantation&#xD;
&#xD;
          4. Budd-Chiari syndrome&#xD;
&#xD;
          5. Unstable hepatic disease (acute hepatitis, AST or ALT &gt; 5 x upper limit of normal,&#xD;
             bilirubin &gt; 10 mg/dL)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <last_update_submitted>August 10, 2010</last_update_submitted>
  <last_update_submitted_qc>August 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2010</last_update_posted>
  <responsible_party>
    <organization>Movetis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

